Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DXS6 | ISIN: US1711261057 | Ticker-Symbol:
NASDAQ
27.03.25
15:38 Uhr
1,600 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CHANNEL THERAPEUTICS CORPORATION Chart 1 Jahr
5-Tage-Chart
CHANNEL THERAPEUTICS CORPORATION 5-Tage-Chart

Aktuelle News zur CHANNEL THERAPEUTICS CORPORATION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.03.Channel Therapeutics Corp - 10-K, Annual Report2
03.03.Channel Therapeutics Corp - 8-K, Current Report-
20.12.24Channel Therapeutics advances non-opioid pain treatment1
20.12.24Channel Therapeutics erzielt Fortschritte bei nicht-opioidhaltiger Schmerztherapie6
20.12.24Channel Therapeutics Corporation: Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine145FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics...
► Artikel lesen
18.12.24Channel Therapeutics Corporation: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model144FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics...
► Artikel lesen
CHANNEL THERAPEUTICS CORPORATION Aktie jetzt für 0€ handeln
21.11.24Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates171"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts...
► Artikel lesen
19.11.24Channel Therapeutics finalizes corporate restructuring-
18.11.24Channel Therapeutics Corp - 8-K, Current Report-
13.11.24Chromocell Therapeutics Corp - 10-Q, Quarterly Report-
24.10.24Chromocell announces amendment to stock repurchase plan1
24.10.24Chromocell boosts stock buyback plan to $750,0001
24.10.24Chromocell Therapeutics Announces Amendment to Stock Repurchase Plan1
24.10.24Chromocell Therapeutics Corp - 8-K, Current Report2
17.04.24Pre-market Movers: INVO Bioscience, iLearningEngines, Vanda Pharmaceuticals, CXApp, Chromocell Therapeutics603LOWELL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.45 A.M. ET).In the Green INVO Bioscience, Inc. (INVO) is up over 73% at $1.35. Vanda...
► Artikel lesen
09.04.24Chromocell Therapeutics Issues Letter to Stockholders from Chief Executive Officer381FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1